Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,796 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06856200Recruiting
Sirolimus plus palbociclib and fulvestrant for advanced breast cancer
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
ShanghaiAges 18 years+ - NCT07333066RecruitingPhase 3
Adding chemotherapy when first treatment response is limited
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
BayonneAges 18 years+ - NCT05093907RecruitingPhase 1/Phase 2
Testing a new cancer drug plus capecitabine for metastatic colon cancer
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
Seoul, Jongro-goAges 19 years+ - NCT07323056RecruitingPhase 2
Neoadjuvant drug combo for stage 3 EGFR-mutant lung cancer
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
ShanghaiAges 18 years+ - NCT07311694RecruitingPhase 3
Comparing a new treatment with standard drugs for advanced prostate cancer
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07309770RecruitingPhase 2
Trastuzumab Rezetecan for advanced solid tumors that have stopped responding to standard treatments
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07309289RecruitingPhase 3
Comparing two drug combos for first-line metastatic colorectal cancer
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
ShanghaiAges 18 years+ - NCT07302763Recruiting
PET imaging to track prostate cancer changes
This study uses special PET scans (up to 4 times) to see how metastatic prostate cancer changes over time. It is for people whose cancer has spread and is still growing after hormone treatments, and who are planning to start chemotherapy or PSMA therapy.
Québec, QuebecAges 18 years+ - NCT07293247RecruitingPhase 2
Targeted radiation after lung cancer surgery
This trial tests if targeted radiation after surgery can help people with non-small cell lung cancer who still have cancer in their lymph nodes after chemotherapy. Participants will have had surgery and chemotherapy before starting radiation.
Jonesboro, ArkansasAges 18 years+ - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Fountain Valley, CaliforniaAges 18 years+ - NCT05816655RecruitingPhase 2
Test two hormone treatment combinations for metastatic breast cancer
This Phase 2 study compares two combinations of hormone-blocking drugs plus an anti-cancer targeted pill to see which works better for hormone-receptor positive, HER2-negative metastatic breast cancer. It may help by finding a more effective treatment plan when the cancer has spread.
SeoulAges 19–80 - NCT07287150RecruitingPhase 2
Testing Inavolisib for advanced prostate cancer
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
Los Angeles, CaliforniaAges 18 years+ - NCT07285382RecruitingPhase 2
Dalpiciclib plus letrozole for advanced HR+ HER2- breast cancer
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
Dalian, LiaoningAges 18–75 - NCT07283575Recruiting
Blood test to monitor metastatic colorectal cancer treatment (PROMET)
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
ShanghaiAges 18–75 - NCT05776524RecruitingPhase 2
Radiofrequency heat treatment for pancreas cancer spread to other organs
This Phase 2 trial tests whether a device that delivers carefully timed “radiofrequency heat” through the body can slow or control metastatic (spread) pancreatic cancer. You may qualify if you have newly diagnosed metastatic pancreatic cancer and can meet safety and blood-test requirements.
Winston-Salem, North CarolinaAges 18 years+ - NCT07260305RecruitingPhase 1
Study of KGX101 alone or with Envafolimab for advanced solid tumors
This trial tests a new drug combination (KGX101 with envafolimab) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if these drugs are safe and could help shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07262567RecruitingPhase 3
New drug vs chemo for KRAS G12D pancreatic cancer
This study tests a new targeted drug, GFH375, against standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the new drug works better and has fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT07263178Recruiting
Second-line chemo for advanced colorectal cancer
This study looks at different chemotherapy options for people with metastatic colorectal cancer that has stopped responding to first treatment. It aims to find which second-line approach works best.
SeoulAges 19 years+ - NCT05299840Recruiting
Test a device to choose the first chemo for metastatic colon cancer
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
MarseilleAges 18 years+ - NCT07258407RecruitingPhase 1/Phase 2
TD001 for men with PSMA-positive metastatic prostate cancer
This trial tests a new drug, TD001, in men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It aims to see if TD001 is safe and effective against tumors that show a specific marker called PSMA.
New Haven, ConnecticutAges 18 years+ - NCT07258563Recruiting
Can a special diet prevent taste changes from chemo?
This study looks at whether a special diet can help prevent taste changes during chemotherapy. It is for people with certain cancers who are about to start treatment.
AmsterdamAges 18–70 - NCT07257471Recruiting
Methylation markers in early-stage lung cancer with ablation therapy
This trial tests if a special treatment called co-ablation can help people with early-stage non-small cell lung cancer who cannot or choose not to have surgery. It also looks at certain markers in the blood to better understand the cancer.
Beijing, Beijing MunicipalityAges 18–85 - NCT07241767RecruitingPhase 2
Study of FH-006 injection with other treatments for lung cancer
This trial tests a new drug called FH-006 combined with other cancer therapies for people with advanced non-small cell lung cancer that cannot be removed with surgery or treated with radiation. It aims to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT07241416RecruitingPhase 3
Rezvilutamide for metastatic hormone-sensitive prostate cancer
This trial tests a new drug, rezvilutamide, combined with standard hormone therapy for men with prostate cancer that has spread but still responds to hormone treatment. The goal is to see if this drug helps control the cancer longer than the usual treatment alone.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,796 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.